Reuters reports that a federal jury has ordered Johnson & Johnson and its DePuy Orthopaedics division to pay $247 million settlment to six patients who suffered from its defective Pinnacle, metal-on-metal, hip implants. in the US. J&J says it will appeal this decision.
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).
Rheumatoid arthritis (RA) is a chronic, inflammatory disease with systemic effects beyond the joints. While RA patients are known to have signficantly higher risks for cardiovascular disease and venous thromboembolic events, an association with stroke (CVA) is unclear.
Reuters reports that U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.
The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.
JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents. (Citation source
A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when
Care to learn what you missed at last weeks ACR 2017 meeting in San Diego? Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers. Another good way to learn from RheumNow.
This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr.
Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !
Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.
Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report). Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
